Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone

Table 2

Clinical efficacy.

	CR	PR	SD	PD	ORR
Control group (n = 40)	12	15	9	4	27 (67.50)
Study group (n = 40)	16	19	3	2	35 (87.50)
χ^2					4.588
					0.032

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, overall response rate.